| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastroenteritis | 10 | 2025 | 26 | 3.570 |
Why?
|
| Hepatitis C, Chronic | 25 | 2025 | 74 | 3.330 |
Why?
|
| Antiviral Agents | 17 | 2025 | 99 | 1.700 |
Why?
|
| Hepatitis B, Chronic | 10 | 2023 | 33 | 1.420 |
Why?
|
| Delivery of Health Care, Integrated | 6 | 2025 | 535 | 1.300 |
Why?
|
| Hepatitis C | 8 | 2023 | 65 | 1.270 |
Why?
|
| Rotavirus | 4 | 2022 | 20 | 1.190 |
Why?
|
| Caliciviridae Infections | 3 | 2025 | 4 | 1.150 |
Why?
|
| Liver Cirrhosis | 11 | 2024 | 41 | 1.100 |
Why?
|
| Humans | 70 | 2025 | 17314 | 1.050 |
Why?
|
| Adult | 46 | 2025 | 7500 | 0.970 |
Why?
|
| Male | 51 | 2025 | 9804 | 0.960 |
Why?
|
| Middle Aged | 44 | 2025 | 7836 | 0.940 |
Why?
|
| Child | 18 | 2025 | 2403 | 0.880 |
Why?
|
| Young Adult | 25 | 2025 | 2465 | 0.860 |
Why?
|
| Female | 51 | 2025 | 12396 | 0.860 |
Why?
|
| Cost of Illness | 1 | 2024 | 92 | 0.830 |
Why?
|
| United States | 29 | 2025 | 3866 | 0.830 |
Why?
|
| Aged | 34 | 2025 | 6084 | 0.780 |
Why?
|
| Herpes Zoster | 1 | 2024 | 82 | 0.780 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2023 | 29 | 0.760 |
Why?
|
| Health Care Costs | 1 | 2024 | 207 | 0.760 |
Why?
|
| Biomarkers | 8 | 2025 | 307 | 0.750 |
Why?
|
| Infant | 12 | 2025 | 1161 | 0.740 |
Why?
|
| Dementia | 1 | 2024 | 121 | 0.730 |
Why?
|
| Adolescent | 22 | 2025 | 3538 | 0.730 |
Why?
|
| Sustained Virologic Response | 6 | 2023 | 19 | 0.670 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2025 | 381 | 0.620 |
Why?
|
| Epidemiological Monitoring | 2 | 2018 | 24 | 0.620 |
Why?
|
| Vaccination | 6 | 2025 | 688 | 0.610 |
Why?
|
| Child, Preschool | 10 | 2025 | 1380 | 0.600 |
Why?
|
| Cohort Studies | 18 | 2025 | 2514 | 0.590 |
Why?
|
| Norovirus | 3 | 2025 | 4 | 0.580 |
Why?
|
| Rotavirus Vaccines | 3 | 2024 | 53 | 0.580 |
Why?
|
| Whooping Cough | 2 | 2018 | 65 | 0.560 |
Why?
|
| Incidence | 9 | 2025 | 1266 | 0.560 |
Why?
|
| Liver Neoplasms | 3 | 2023 | 42 | 0.510 |
Why?
|
| Hepacivirus | 10 | 2024 | 52 | 0.500 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 33 | 0.450 |
Why?
|
| Hepatitis B | 3 | 2023 | 45 | 0.440 |
Why?
|
| Influenza Vaccines | 2 | 2024 | 292 | 0.430 |
Why?
|
| Immunization, Secondary | 2 | 2013 | 59 | 0.430 |
Why?
|
| Rotavirus Infections | 3 | 2022 | 33 | 0.400 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2025 | 4 | 0.400 |
Why?
|
| Positron-Emission Tomography | 3 | 2020 | 33 | 0.400 |
Why?
|
| Oregon | 8 | 2025 | 170 | 0.380 |
Why?
|
| Papillomavirus Vaccines | 1 | 2013 | 114 | 0.380 |
Why?
|
| Retrospective Studies | 9 | 2024 | 2415 | 0.370 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 131 | 0.370 |
Why?
|
| Coinfection | 3 | 2023 | 31 | 0.370 |
Why?
|
| Time Factors | 10 | 2019 | 1039 | 0.360 |
Why?
|
| Amyloid | 2 | 2021 | 3 | 0.340 |
Why?
|
| Feces | 2 | 2022 | 85 | 0.330 |
Why?
|
| HIV Infections | 3 | 2017 | 712 | 0.290 |
Why?
|
| Pancreatic Neoplasms | 2 | 2021 | 69 | 0.290 |
Why?
|
| Washington | 6 | 2025 | 384 | 0.290 |
Why?
|
| Electronic Health Records | 4 | 2025 | 704 | 0.280 |
Why?
|
| Risk Factors | 10 | 2025 | 3258 | 0.280 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 21 | 0.270 |
Why?
|
| Acute Disease | 2 | 2025 | 144 | 0.270 |
Why?
|
| African Americans | 5 | 2020 | 439 | 0.260 |
Why?
|
| Risk Assessment | 5 | 2023 | 1076 | 0.260 |
Why?
|
| Diarrhea | 2 | 2023 | 12 | 0.250 |
Why?
|
| Age Factors | 6 | 2024 | 878 | 0.250 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2025 | 26 | 0.240 |
Why?
|
| Health Status | 2 | 2020 | 293 | 0.240 |
Why?
|
| Alkaline Phosphatase | 1 | 2025 | 9 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 367 | 0.240 |
Why?
|
| Prospective Studies | 8 | 2023 | 1226 | 0.240 |
Why?
|
| Intention | 1 | 2025 | 30 | 0.230 |
Why?
|
| Influenza, Human | 2 | 2024 | 282 | 0.230 |
Why?
|
| Metapneumovirus | 1 | 2025 | 5 | 0.230 |
Why?
|
| Paramyxoviridae Infections | 1 | 2025 | 6 | 0.230 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2025 | 7 | 0.230 |
Why?
|
| Hepatitis B virus | 3 | 2023 | 25 | 0.230 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2025 | 19 | 0.230 |
Why?
|
| Seasons | 1 | 2025 | 113 | 0.230 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2024 | 1 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 25 | 0.230 |
Why?
|
| Narcolepsy | 1 | 2024 | 9 | 0.230 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2025 | 29 | 0.220 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 1151 | 0.220 |
Why?
|
| Healthy Volunteers | 2 | 2021 | 4 | 0.220 |
Why?
|
| History, 21st Century | 1 | 2024 | 25 | 0.220 |
Why?
|
| Aminoisobutyric Acids | 1 | 2024 | 2 | 0.220 |
Why?
|
| Cyclopropanes | 1 | 2024 | 2 | 0.220 |
Why?
|
| Lactams, Macrocyclic | 1 | 2024 | 2 | 0.220 |
Why?
|
| Benzimidazoles | 1 | 2024 | 6 | 0.220 |
Why?
|
| Proline | 1 | 2024 | 6 | 0.210 |
Why?
|
| Sulfonamides | 1 | 2024 | 15 | 0.210 |
Why?
|
| Leucine | 1 | 2024 | 5 | 0.210 |
Why?
|
| Herpesvirus 3, Human | 1 | 2024 | 44 | 0.210 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 1925 | 0.210 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2023 | 10 | 0.200 |
Why?
|
| Latent Tuberculosis | 1 | 2023 | 11 | 0.200 |
Why?
|
| Quality of Life | 3 | 2023 | 499 | 0.200 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2025 | 151 | 0.200 |
Why?
|
| Parents | 1 | 2025 | 297 | 0.190 |
Why?
|
| Ribavirin | 2 | 2019 | 8 | 0.190 |
Why?
|
| Insulins | 1 | 2022 | 1 | 0.190 |
Why?
|
| Surveys and Questionnaires | 5 | 2025 | 1282 | 0.190 |
Why?
|
| Liver | 3 | 2017 | 34 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 664 | 0.190 |
Why?
|
| Aspartate Aminotransferases | 3 | 2020 | 14 | 0.190 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 268 | 0.180 |
Why?
|
| Alanine Transaminase | 3 | 2020 | 23 | 0.180 |
Why?
|
| Population Surveillance | 1 | 2003 | 252 | 0.180 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 271 | 0.180 |
Why?
|
| Neurology | 1 | 2021 | 7 | 0.180 |
Why?
|
| Prevalence | 6 | 2023 | 840 | 0.180 |
Why?
|
| tau Proteins | 1 | 2021 | 4 | 0.180 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2021 | 1 | 0.180 |
Why?
|
| Hippocampus | 1 | 2021 | 8 | 0.180 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 34 | 0.180 |
Why?
|
| Internship and Residency | 1 | 2021 | 49 | 0.170 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 437 | 0.170 |
Why?
|
| Body Mass Index | 1 | 2024 | 937 | 0.160 |
Why?
|
| Cholagogues and Choleretics | 1 | 2020 | 2 | 0.160 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 2 | 0.160 |
Why?
|
| International Classification of Diseases | 2 | 2017 | 86 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2020 | 49 | 0.160 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 173 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2024 | 1160 | 0.150 |
Why?
|
| Logistic Models | 3 | 2019 | 879 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 2 | 0.150 |
Why?
|
| Brain | 2 | 2016 | 48 | 0.150 |
Why?
|
| RNA, Viral | 2 | 2019 | 65 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2020 | 134 | 0.150 |
Why?
|
| Diabetes, Gestational | 1 | 2022 | 311 | 0.150 |
Why?
|
| Virus Activation | 1 | 2018 | 5 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2018 | 108 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 46 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 22 | 0.140 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 390 | 0.140 |
Why?
|
| Mental Health | 2 | 2020 | 169 | 0.140 |
Why?
|
| Data Mining | 1 | 2017 | 16 | 0.140 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2018 | 88 | 0.130 |
Why?
|
| Community Health Centers | 1 | 2017 | 64 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 86 | 0.130 |
Why?
|
| Europe | 3 | 2021 | 46 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1098 | 0.130 |
Why?
|
| Viral Load | 1 | 2017 | 136 | 0.130 |
Why?
|
| Alcoholism | 2 | 2017 | 337 | 0.130 |
Why?
|
| Molecular Imaging | 1 | 2016 | 1 | 0.130 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 12 | 0.130 |
Why?
|
| Gastroenterology | 1 | 2016 | 19 | 0.130 |
Why?
|
| Data Collection | 2 | 2014 | 238 | 0.120 |
Why?
|
| Serum | 1 | 2016 | 5 | 0.120 |
Why?
|
| Integrins | 1 | 2016 | 1 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 2016 | 2 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2016 | 15 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 10 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 9 | 0.120 |
Why?
|
| Liver Failure | 1 | 2015 | 2 | 0.120 |
Why?
|
| Depression | 2 | 2017 | 486 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2016 | 157 | 0.120 |
Why?
|
| Pertussis Vaccine | 1 | 2015 | 14 | 0.110 |
Why?
|
| Vietnam Conflict | 1 | 2014 | 2 | 0.110 |
Why?
|
| Hepatitis A | 1 | 2014 | 11 | 0.110 |
Why?
|
| Hepatitis C Antibodies | 1 | 2014 | 4 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 8 | 0.110 |
Why?
|
| Fluorine Radioisotopes | 1 | 2014 | 1 | 0.110 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2014 | 2 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 5 | 0.110 |
Why?
|
| Cause of Death | 3 | 2021 | 176 | 0.110 |
Why?
|
| European Continental Ancestry Group | 3 | 2020 | 476 | 0.110 |
Why?
|
| Off-Label Use | 1 | 2013 | 14 | 0.110 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2013 | 32 | 0.100 |
Why?
|
| Sex Factors | 3 | 2024 | 603 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2013 | 121 | 0.100 |
Why?
|
| Veterans | 1 | 2014 | 145 | 0.100 |
Why?
|
| Asian Americans | 3 | 2020 | 163 | 0.100 |
Why?
|
| Platelet Count | 3 | 2017 | 13 | 0.100 |
Why?
|
| Smoking | 1 | 2015 | 429 | 0.090 |
Why?
|
| Disease Progression | 3 | 2020 | 259 | 0.090 |
Why?
|
| Hospitalization | 3 | 2022 | 804 | 0.090 |
Why?
|
| Health Maintenance Organizations | 1 | 2013 | 407 | 0.090 |
Why?
|
| Animals | 3 | 2018 | 280 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 535 | 0.090 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 605 | 0.090 |
Why?
|
| Biopsy | 3 | 2015 | 82 | 0.090 |
Why?
|
| Vaccines, Inactivated | 1 | 2010 | 72 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 4 | 0.080 |
Why?
|
| Meningitis, Meningococcal | 1 | 2010 | 7 | 0.080 |
Why?
|
| Adenovirus Infections, Human | 1 | 2009 | 1 | 0.080 |
Why?
|
| Adenoviruses, Human | 1 | 2009 | 1 | 0.080 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2014 | 34 | 0.080 |
Why?
|
| Health Surveys | 2 | 2020 | 245 | 0.070 |
Why?
|
| Pregnancy | 2 | 2025 | 1463 | 0.070 |
Why?
|
| Fever | 2 | 2023 | 54 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2020 | 640 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2022 | 805 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 701 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 560 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 357 | 0.060 |
Why?
|
| Social Support | 2 | 2020 | 207 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 674 | 0.060 |
Why?
|
| Hispanic Americans | 2 | 2020 | 375 | 0.060 |
Why?
|
| Climate | 1 | 2025 | 4 | 0.060 |
Why?
|
| Rats | 2 | 2016 | 35 | 0.060 |
Why?
|
| Humidity | 1 | 2025 | 3 | 0.060 |
Why?
|
| Mitochondria | 1 | 2025 | 8 | 0.060 |
Why?
|
| Temperature | 1 | 2025 | 19 | 0.060 |
Why?
|
| Critical Care | 2 | 2020 | 66 | 0.060 |
Why?
|
| Prognosis | 2 | 2017 | 603 | 0.060 |
Why?
|
| Bias | 1 | 2025 | 96 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 342 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 298 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2016 | 170 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2024 | 2 | 0.050 |
Why?
|
| Pruritus | 1 | 2023 | 3 | 0.050 |
Why?
|
| Quinoxalines | 1 | 2024 | 12 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 32 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2024 | 163 | 0.050 |
Why?
|
| Genotype | 1 | 2024 | 223 | 0.050 |
Why?
|
| Body Weight | 1 | 2024 | 203 | 0.050 |
Why?
|
| Heterosexuality | 1 | 2003 | 8 | 0.050 |
Why?
|
| Homosexuality | 1 | 2003 | 5 | 0.050 |
Why?
|
| Michigan | 1 | 2003 | 28 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2003 | 13 | 0.050 |
Why?
|
| Sexual Partners | 1 | 2003 | 38 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2003 | 63 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 452 | 0.050 |
Why?
|
| Women's Health | 1 | 2003 | 197 | 0.050 |
Why?
|
| Medical Records | 2 | 2014 | 91 | 0.050 |
Why?
|
| Internet | 1 | 2023 | 212 | 0.050 |
Why?
|
| Neurologists | 1 | 2021 | 2 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 1280 | 0.040 |
Why?
|
| Curriculum | 1 | 2021 | 36 | 0.040 |
Why?
|
| Germinal Center | 1 | 2021 | 1 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 11 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 5 | 0.040 |
Why?
|
| Survivorship | 1 | 2021 | 12 | 0.040 |
Why?
|
| Vaccines, Attenuated | 1 | 2021 | 45 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 43 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 158 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 102 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2020 | 6 | 0.040 |
Why?
|
| Unemployment | 1 | 2020 | 12 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 266 | 0.040 |
Why?
|
| Bilirubin | 1 | 2020 | 31 | 0.040 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 33 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 37 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 171 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2021 | 225 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 252 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2020 | 99 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 107 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 5 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 43 | 0.040 |
Why?
|
| Cell Fusion | 1 | 2018 | 1 | 0.040 |
Why?
|
| Hybrid Cells | 1 | 2018 | 1 | 0.040 |
Why?
|
| Karyotyping | 1 | 2018 | 1 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 2 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 4 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 12 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2018 | 5 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 20 | 0.040 |
Why?
|
| Macrophages | 1 | 2018 | 9 | 0.040 |
Why?
|
| Cell Survival | 1 | 2018 | 11 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 202 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 47 | 0.040 |
Why?
|
| Glycated Hemoglobin A | 1 | 2019 | 184 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 287 | 0.040 |
Why?
|
| Clinical Enzyme Tests | 1 | 2017 | 1 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2017 | 4 | 0.030 |
Why?
|
| Fibrosis | 1 | 2017 | 7 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 145 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 123 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2017 | 56 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 180 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 314 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 239 | 0.030 |
Why?
|
| Medicine | 1 | 2016 | 18 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2016 | 1 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2016 | 5 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2016 | 5 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 6 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 5 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 7 | 0.030 |
Why?
|
| Mamastrovirus | 1 | 2016 | 1 | 0.030 |
Why?
|
| Astroviridae Infections | 1 | 2016 | 1 | 0.030 |
Why?
|
| Sapovirus | 1 | 2016 | 1 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 14 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 8 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 31 | 0.030 |
Why?
|
| CCCTC-Binding Factor | 1 | 2016 | 1 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 11 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 814 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2016 | 34 | 0.030 |
Why?
|
| Genome, Human | 1 | 2016 | 34 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 184 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 111 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 51 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 103 | 0.030 |
Why?
|
| Mutation | 1 | 2016 | 132 | 0.030 |
Why?
|
| Medicare | 1 | 2016 | 192 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 202 | 0.030 |
Why?
|
| Medicaid | 1 | 2016 | 189 | 0.030 |
Why?
|
| Hepatitis A Antibodies | 1 | 2014 | 3 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 7 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2015 | 82 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 15 | 0.030 |
Why?
|
| Hepatitis A Vaccines | 1 | 2014 | 15 | 0.030 |
Why?
|
| Radioactive Tracers | 1 | 2014 | 1 | 0.030 |
Why?
|
| Radiochemistry | 1 | 2014 | 1 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2014 | 1 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 2014 | 3 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 2 | 0.030 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 44 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 356 | 0.030 |
Why?
|
| Mice | 1 | 2014 | 80 | 0.030 |
Why?
|
| Pathology | 1 | 2014 | 5 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2019 | 726 | 0.030 |
Why?
|
| California | 1 | 2020 | 2311 | 0.030 |
Why?
|
| Hypertension | 1 | 2017 | 469 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2016 | 451 | 0.020 |
Why?
|
| Neoplasms | 1 | 2017 | 446 | 0.020 |
Why?
|
| Research Design | 1 | 2014 | 336 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 425 | 0.020 |
Why?
|
| Serotyping | 1 | 2009 | 3 | 0.020 |
Why?
|
| Oxygen | 1 | 2009 | 16 | 0.020 |
Why?
|
| Cross Infection | 1 | 2009 | 25 | 0.020 |
Why?
|